Phenylalanine-coupled solid lipid nanoparticles (SLN) loaded with doxorubicin, a chemotherapy drug, have been shown to target LAT1 in the blood-brain barrier, as well as in brain cancer cells, where it is highly expressed, significantly enhancing the delivery of that drug and its anti-cancer activity [188]. The gene discussed is SLC7A5; the disease is cancer.